Entrada Therapeutics Alternatives & Competitors
3 companies similar to Entrada Therapeutics — Innovating to transform the treatment of serious diseases through establishing a...
Companies similar to Entrada Therapeutics
Dyne Therapeutics
Advancing life-transforming therapies for serious muscle diseases
Waltham, United States
PepGen
Better Technology. Better Delivery. Developing a new generation of disease-modifying thera...
Boston, United States
Yaqrit
The Liver Disease Company
London, United Kingdom
About Entrada Therapeutics
Entrada Therapeutics, founded in 2016, is a clinical-stage biopharmaceutical company based in Boston’s Seaport community. The company is committed to transforming therapeutic approaches for challenging diseases by focusing on intracellular targets previously deemed unreachable. With a mission encapsulated in their slog...
Development of intracellular therapeutics, Clinical trials, Research on undruggable targets, Development of disease-specific therapies
Patients with neuromuscular disorders, Families affected by Duchenne Muscular Dystrophy, Researchers and medical professionals, Biotechnology investors
Intracellular Therapeutics, Genetic Medicines, Neuromuscular Diseases, Inherited Retinal Diseases, Oligonucleotide Programs, Duchenne Muscular Dystrophy, Exon Skipping, Myotonic Dystrophy Type 1, Clinical-stage Biopharmaceutical, Boston Seaport Community, Proprietary Approaches, Versatile And Modular Development, Biopharma Innovation, Disease Transformation
B2B, B2D
Licensing, Product Sales, Service Fee
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around Entrada Therapeutics: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at Entrada Therapeutics on 9 Jun 2026. The 3 companies listed here were last checked between 11 Mar 2026 and 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
